Pro-Pharmaceuticals (PRW) Reports Positive Phase II Data of DAVANAT in Combination with 5-fluorouracil
Tweet Send to a Friend
Pro-Pharmaceuticals, Inc. (Amex: PRW) announced that data of all end-stage colorectal cancer patients from its Phase II trial showed DAVANAT ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
